Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin) Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Corneal Neovascularization

abstract

  • Topically administered bevacizumab (Avastin) at a concentration of 4 mg/ml limits corneal neovascularisation following chemical injury in the male Long Evans rat model.

publication date

  • June 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC1955569

Digital Object Identifier (DOI)

  • 10.1136/bjo.2006.107912

PubMed ID

  • 17179168

Additional Document Info

start page

  • 804

end page

  • 7

volume

  • 91

number

  • 6